Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 03 Sep 2025
FDA accepts Shionogi’s ensitrelvir NDA as the first oral therapy for the prevention of COVID-19 following exposure
2 September 2025 - Shionogi announced the US FDA has accepted a new drug application for ensitrelvir fumaric acid, an investigational ...
Posted by Michael Wonder on 03 Sep 2025
Rolling sBLA initiated to the US FDA for Leqembi Iqlik (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under fast track status
3 September 2025 - BioArctic partner Eisai announced today that they have initiated a rolling submission of the supplemental biologics license ...
Posted by Michael Wonder on 03 Sep 2025
ICER publishes final evidence report on treatments for spinal muscular atrophy
2 September 2025 - Independent appraisal committee votes reflect uncertainty in net health benefit for apitegromab and for add-on treatments ...
Posted by Michael Wonder on 03 Sep 2025
'More than my rent': NSW woman's $1000 a month fight for relief
3 September 2025 - Six years ago, Raphaella Kathryn Crosby could barely get out of bed. ...
Posted by Michael Wonder on 03 Sep 2025
Health Canada approves Elahere for certain types of platinum-resistant ovarian cancers
2 September 2025 - Elahere received approval through Health Canada's priority review process, based on data from the pivotal MIRASOL Phase ...
Posted by Michael Wonder on 02 Sep 2025
DoH publishes revised agenda for September 2025 PBAC meeting (version 2)
2 September 2025 - The agenda for the September 2025 PBAC meeting has now been updated. ...
Posted by Michael Wonder on 02 Sep 2025
Multiple myeloma drug Darzalex to get expanded coverage from September
29 August 2025 - Starting in September, reimbursement for the multiple myeloma treatment Darzalex (daratumumab) will be expanded, reducing the ...
Posted by Michael Wonder on 02 Sep 2025
Cost of PBS scripts to be dropped to $25 from January 1 2026
2 September 2025 - Prescriptions listed on the PBS will be cut from $31.60 to $25 from January 1, 2026, ...
Posted by Michael Wonder on 02 Sep 2025
New free vaccine to protect kids against pneumococcal
2 September 2025 - Australian children will now have stronger protection against pneumococcal with the Australian Government implementing a new ...
Posted by Michael Wonder on 01 Sep 2025
PHARMAC confirms continued access to Comirnaty COVID-19 vaccine
1 September 2025 - PHARMAC has secured a new supply agreement with Pfizer to continue funding the Comirnaty brand of ...
Posted by Michael Wonder on 01 Sep 2025
Care for people with rare and less common cancers ‘delayed and fragmented’, new report reveals
1 September 2025 - A national survey of nearly 2,500 people affected by cancer has found those with a rare ...
Posted by Michael Wonder on 01 Sep 2025
More cheaper medicines now available for Australians
1 September 2025 - From today, Australians with paediatric psoriasis, fibrodysplasia, asthma, cystic fibrosis and blood cancer now have access ...
Posted by Michael Wonder on 01 Sep 2025
Schedule of Pharmaceutical Benefits - 1 September 2025
1 September 2025 - The September 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Sep 2025
New Zealand Pharmaceutical Schedule - 1 September 2025
1 September 2025 - The September 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Aug 2025
Moderna receives US FDA approval for updated COVID-19 vaccines targeting LP.8.1 variant of SARS-CoV-2
27 August 2025 - Moderna today announced that the US FDA has approved the supplemental biologics license applications for the ...